{"id":"amodiaquine-artesunate-versus-amodiaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amodiaquine is a 4-aminoquinoline that inhibits heme polymerization in malaria parasites, while artesunate is a semi-synthetic artemisinin derivative that generates reactive oxygen species and damages parasite proteins. The combination provides rapid parasite clearance (artesunate) with sustained suppression (amodiaquine), reducing treatment duration and improving efficacy against drug-resistant strains.","oneSentence":"Amodiaquine-artesunate is a fixed-dose combination antimalarial that combines a quinoline derivative with a fast-acting artemisinin to kill malaria parasites through multiple mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:21.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria (Plasmodium falciparum and other species)"},{"name":"Malaria treatment in endemic regions"}]},"trialDetails":[{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1680},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT03768908","phase":"PHASE4","title":"Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2005-01-05","conditions":"Plasmodium Falciparum Malaria","enrollment":359},{"nctId":"NCT03764527","phase":"PHASE4","title":"Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2002-11-01","conditions":"Plasmodium Falciparum Malaria","enrollment":408},{"nctId":"NCT00119132","phase":"PHASE2, PHASE3","title":"Effectiveness of Intermittent Preventive Treatment for Malaria in Children","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2005-06","conditions":"Malaria","enrollment":2602},{"nctId":"NCT00432367","phase":"PHASE3","title":"Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2007-02","conditions":"Malaria, Anaemia, Pregnancy","enrollment":3333},{"nctId":"NCT01017770","phase":"PHASE4","title":"Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-09","conditions":"Uncomplicated P. Falciparum Malaria in Children","enrollment":340},{"nctId":"NCT01378286","phase":"PHASE3","title":"Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Malaria","enrollment":380},{"nctId":"NCT00164359","phase":"PHASE4","title":"Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-04","conditions":"Malaria, Falciparum","enrollment":212},{"nctId":"NCT00540410","phase":"PHASE4","title":"Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Malaria","enrollment":366},{"nctId":"NCT00563914","phase":"PHASE1, PHASE2","title":"A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Malaria","enrollment":72},{"nctId":"NCT00316329","phase":"PHASE3","title":"ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Malaria","enrollment":1032},{"nctId":"NCT00460369","phase":"NA","title":"Treatment of Uncomplicated Malaria in Benin","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2007-04","conditions":"Uncomplicated Malaria","enrollment":240},{"nctId":"NCT00445796","phase":"PHASE4","title":"Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-06","conditions":"Malaria","enrollment":300},{"nctId":"NCT00374205","phase":"PHASE4","title":"Randomized Trial on Effectiveness of ACTs in Ghana","status":"TERMINATED","sponsor":"Bernhard Nocht Institute for Tropical Medicine","startDate":"2006-09","conditions":"Malaria, Falciparum","enrollment":245},{"nctId":"NCT00238017","phase":"PHASE4","title":"Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2005-10","conditions":"Malaria","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"amodiaquine-artesunate versus amodiaquine","genericName":"amodiaquine-artesunate versus amodiaquine","companyName":"Charite University, Berlin, Germany","companyId":"charite-university-berlin-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amodiaquine-artesunate is a fixed-dose combination antimalarial that combines a quinoline derivative with a fast-acting artemisinin to kill malaria parasites through multiple mechanisms. Used for Uncomplicated malaria (Plasmodium falciparum and other species), Malaria treatment in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}